Background Minimal-change nephrotic syndrome (MCNS) is treated by the administration of prednisolone (PSL) at high doses. Steroid-induced osteoporosis is a serious adverse effect of this drug. Methods Patients with MCNS were randomly assigned to two groups, the risedronate (2.5 mg/day) + alfacalcidol (0.25 μg/day) group (n=20) and the alfacalcidol (0.25 μg/day)-alone group (n=20). All the patients had received PSL and the clinical characteristics were compared between the two groups at baseline and at 12 months. Results A significant decrease of the mean bone mineral density (BMD) of the lumbar spine from 0.710± 0.162 (g/cm 2 ) to 0.588±0.125 was observed in the alfacalcidol-alone group (p=0.02), while no such decrease of the bone mineral density was found in the risedronate + alfacalcidol group (0.663±0.169 at baseline and 0.626±0.129 at 12 months). No significant differences in the results of other biochemical tests performed at the baseline and at 12 months were observed between the two groups. The likelihood of development of steroid-induced osteoporosis was influenced by the cumulative dose of PSL, the mean BMD at the baseline, occurrence of disease relapse, and risedronate therapy. Conclusion Risedronate appears to be effective in preventing steroid-induced osteoporosis. It is necessary to use bisphosphonates to maintain the BMD in patients with MCNS receiving prolonged steroid therapy.
Introduction
Corticosteroid therapy is used as the first-line therapy for minimal-change nephrotic syndrome (MCNS). Adults with MCNS generally receive prednisolone (PSL) in accordance with their body weight in kilograms (1.0 mg/kg/day). While the remission rate with this treatment in patients with MCNS is about 80%, relapses are frequent. The frequent occurrence of relapses in cases of MCNS may necessitate repeated courses of treatment with high doses of PSL (1, 2) .
Prolonged administration of corticosteroids is, however, associated with a high risk of steroid toxicity. Osteoporosis, an adverse effect of PSL, is a serious complication. Generally speaking, steroid-induced osteoporosis is observed within the first 6-12 months after the start of therapy and several studies have suggested that the risk of bone fracture is doubled in patients receiving steroids at more than the equivalent of 7.5 mg/day of PSL (3) (4) (5) (6) . Steroid-induced osteoporosis is characterized by the loss of bone mass and microarchitectural integrity, resulting in increased bone fragility and an elevated risk of fractures, with associated morbidity and mortality. The most vulnerable sites for steroid-induced osteoporosis are the trabecular bones, such as the vertebrae, ribs and hip bones (7) (8) (9) .
The optimal dose and duration of corticosteroid therapy, or the optimum administration schedule to avoid corticosteroid toxicity, have yet to be established in patients with MCNS. Several trials on the treatment of steroid-induced osteoporosis have been carried out recently, and favorable results have been reported (10) (11) (12) (13) . To the best of our knowledge, there are no reports of the use of bisphoshonates for the prevention of steroid-induced osteoporosis in adult patients of MCNS, although the use of bisphosphonates for steroid-induced osteoporosis in children with nephropathy (14) and adults with glomerulonephritis (15) has been reported previously.
Methods

Study design
The study was a prospective randomized parallel-group open-label trial. Eligible patients, consisting of patients with minimal-change nephrotic syndrome, were randomly assigned by the trial nephrologists to treatment with risedronate + alfacalcidol (risedronate+alfacalcidol group) or alfacalcidol alone (alfacalcidol-alone group). The risedronate + alfacalcidol group received risedronate (Benet; Takeda Pharmaceutical Co., Osaka, Japan) at 2.5 mg/day+alfacalcidol at 0.25 μg/day. The alfacalcidol-alone group received only oral alfacalcidol at the dose of 0.25 μg/day. Randomization was performed by a simple randomization method in a 1 : 1 fashion using a random number generator. The randomization sequence was kept concealed by the secretary until the end of the trial. The study was conducted with the approval of the Institute's Ethics Committee, after obtaining written informed consent from each patient.
Patients
We enrolled Japanese adults (older than 18 years old) with biopsy-proven minimal-change disease in this study. All of the patients were receiving treatment with oral prednisolone (0.8-1.0 mg/kg/day). The duration of the initial daily corticosteroid therapy varied from 4 to 6 weeks, depending mostly on the pattern of response. Thereafter, the daily dose was reduced by 10 mg every 4 weeks. The dose reduction by 10 mg every 4 weeks was continued and maintained for at least 12 months, although the protocol for tapering the steroid dosage was not stringently restricted. Patients showing 'relapse' were administered intravenous pulse methylprednisolone therapy, and/or therapy with cyclosporin at the dose of AUC1700 to 2,000 ng/mL. All of the patients who were diagnosed at the Department of Medicine of the Kidney Center of Tokyo Women's Medical University between 2003 and 2008 were admitted to our nephrology department and enrolled in this study.
Definitions
Nephrotic syndrome is defined as urinary protein excretion of 3.5 g/day, serum albumin of <3.0 g/dL, edema, and hyperlipidemia. A patient was defined as showing 'relapse' when the trial nephrologists judged it necessary to step up the immunosuppressive therapy, supported by a daily urinary protein excretion of >3.5 g, as represented by the results of a urine dipstick test for albumin of 3+ or 4+. 'Complete remission' was defined as clinical improvement supported by a daily urinary protein excretion of <0.3 g, as represented by a result of the urine dipstick test for albumin of 'trace', or a negative urine dipstick test for albumin.
Follow-up
The clinical data evaluated were the age, weight (kg), height (cm), BMI, and laboratory data, including the BMD at the lumbar spine (L2-4: g/cm 2 , T-score, Z-score), urinary protein excretion (UP, g/day), serum albumin (Alb, g/dL), serum creatinine (S-Cre, mg/dL), serum calcium (Ca, mg/ dL), serum alkaline phosphatase (ALP, IU/L), urinary Ntelopeptide cross-links of type 1 collagen (NTx, nmolBCE/ mmol Cre), and the cumulative dose of PSL (g). Patients were examined before the administration of PSL, that is, at the baseline, and after 12 months of treatment with prednisolone.
Statistical analysis
Data were expressed as the mean ± standard deviation (SD). The significance of differences between groups was examined by the Student's t-test for nonpaired samples and by the χ 2 -test. Changes from the baseline observed at the 12-month observation were compared between the risedronate+alfacalcidol group and the alfacalcidol-alone group using the t-test. When differences could be demonstrated, the values were compared with those at the baseline using the paired-sample t-test; p values of <0.05 were considered to indicate statistical significance. Stepwise multiple regression analysis was used to select independent risk factors among the parameters selected by the univariate analysis. Parameters with an F value of more than 4 were adopted. P values of less than 0.05 were considered to be statistically significant.
Results
A total of 40 patients met the enrollment criteria and provided consent for participation in the study. The primary endpoints could be analyzed in all of the patients at the end of the 12-month observation period. All of the patients entered complete remission by 4 weeks. The baseline demographic and biochemical parameters were comparable with those measured after 12 months' treatment in both groups ( Table 1 ). The BMD decreased by 7.7±18.5% from the baseline to the observation at 12 months (0.681±0.171 g/cm 
T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s o f P a t i e n t s wi t h Mi n i ma l Ch a n g e Ne p h r o t i c S y n d r o me b e t we e n B a s e l i n e a n d t h e T i me a f t e r 1 Ye a r
Sex (female: male) Age (years) BMI(kg/m 2 ) UP(g/day) Alubumine(g/dL) Serum creatinine (mg/dL) eGFR(ml/min) Ca(mg/dL) ALP(IU/L) NTx(nmolBCE/mmol Cr) Lumbar spine BMD(g/cm 2 ) T-score(SD) Z-score(SD) The cumulative dose of PSL(g) Relapse(n)
T a b l e 2 . Ch a n g e s i n Cl i n i c a l P a r a me t e r s i n t h e Ri s e d r o n a t e + Al f a c a l c i d o l a n d Al f a c a l c i d o l Gr o u p s
Risedronate+alfacalcidol ( The cumulative dose of PSL was 10.5±5.9 g. Twenty patients were assigned to the risedronate+alfacalcidol group and 20 to the alfacalcidol-alone group. Both groups included 3 postmenopausal women each. Ten patients in the risedronate+alfacalcidol group and nine patients in the alfacalcidolalone group developed relapse during the 12-month observation period. There were no significant differences in any of the parameters examined, including the gender distribution, average age, BMI, BMD, UP, Alb, S-Cre, Ca, ALP, and NTx between the risedronate+alfacalcidol group and the alfacalcidol-alone group.
In the alfacalcidol-alone group, the BMD decreased from 0.710±0.162 g/cm 2 at baseline to 0.588±0.125 g/cm 2 at the 12-month observation (p=0.02). Conversely, there was no significant change in the BMD in the risedronate+alfacalci-dol, (0.663±0.169 g/cm 2 at baseline, 0.626±0.129 g/cm 2 at 12 months) (p=NS) ( Table 2) . A tendency towards decrease of the serum ALP during the 12-month observation period was observed in both the risedronate + alfacalcidol group (191.5±65.8 IU/L at the baseline to 165.5±51.7 IU/L at 12 months; p=0.09) and the alfacalcidol-alone group (175.9± 38.5 IU/L at the baseline to 140.0±51.1 IU/L at 12 months; p=0.06). Comparison of the two groups revealed that the deterioration of the BMD ( BMD/baseline BMD) at 12 months was significantly lower in the risedronate+alfacalci-dol group than in the alfacalcidol-alone group. A tendency Significant decrease of the U-P during the 12-month follow-up period was observed in the risedronate+alfacalci-dol group (5.2±2.7 g/day at the baseline to 1.1±2.1 g/day at 12 months; p<0.0001) as well as in the alfacalcidol-alone group (5.5±2.9 g/day at the baseline to 0.1±0.3 g/day at 12 months; p<0.0001). Significant increase of the serum Alb was observed in the risedronate+alfacalcidol group (2.5±0.7 g/dL at the baseline to 3.6±0.8 g/dL at 12 months; p< 0.0001) as well as in the alfacalcidol-alone group (2.3±0.9 at the baseline to 4.1±0.3 at 12 months; p<0.0001) at the 12-month observation as compared with the levels at the baseline. There were no significant differences in the S-Cre, eGFR, or Ca levels between the values measured at the baseline and at 12 months in either group (Table 2) .
T a b l e 3 . Mu l t i p l e Re g r e s s i o n An a l y s i s f o r Ri s k F a c t o r s o f B MD De t e r i o r a t i o n ( Δ B MD/ P r e B MD)
There were no significant differences in the UP, Alb, SCre, eGFR, Ca, ALP, BMD, relapse or the cumulative dose of PSL at the 12-month observation between the two groups ( Table 2 ).
In addition, we analyzed the independent risk factors for deterioration of the BMD ( BMD/baseline BMD). Multiple regression analysis (Table 3) identified the baseline BMD (p=0.006), administration of risedoronate (p=0.03), occurrence of relapse (p=0.04) and the cumulative dose of PSL (p=0.007) as independent risk factors influencing the risk of deterioration of the BMD.
There were no major adverse events during the observation period.
Discussion
Osteoporosis and bone fracture are major adverse effects of corticosteroid therapy. Cocorticosteroids suppress the differentiation of osteoblastic cells and enhance the apoptosis of mature osteoblasts, which result in a decrease of bone formation (16) . It has also been reported that long-term steroid therapy may cause osteoporosis or exacerbate a preexisting osteoporotic condition and lead to pathologic fractures in up to 50% of patients, although the precise incidence remains unknown (17) (18) (19) .
Corticosteroid therapy is used in the management of various inflammatory diseases such as asthma, rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease (20) (21) (22) . Corticosteroids are also the therapeutic agents of first choice for the treatment of renal diseases such as NS and glomerulonephritis. NS, when persistent, often results in a number of biochemical and metabolic disturbances. These are mainly attributed to the loss of a variety of plasma proteins and minerals in the urine. Abnormalities of calcium metabolism in patients with NS are also well recognized. Although the onset of renal insufficiency may also contribute to the development of these metabolic abnormalities, these abnormalities have been found even in patients with no impairment of renal function. The serum concentration of 25-hydroxyvitamin D is reduced in patients with NS, because of the loss of vitamin D-binding protein in the urine. Osteomalacia and hyperparathyroidism have recently been reported to occur as a consequence of the low levels of 25-hydroxyvitamin D (25OHD) (23) (24) (25) (26) . Sanjeev et al reported that osteomalacia (OCM) is a frequent finding on histomorphometric analysis in adult patients with NS, including minimal-change nephrotic syndrome, and its severity has been shown to be well-correlated with the duration and the amount of proteinuria (27) .
In the present study, we focused on steroid-induced bone loss in patients with minimal-change nephrotic syndrome.
Significant decreases of the serum ALP, urinary NTx and BMD were observed at 12 months as compared with the levels measured at the baseline in the patients receiving steroid therapy without any supportive therapy. This was supported by the finding that the serum ALP levels were also decreased, because ALP is synthesized in poorly differentiated osteoblastic cells. The change in the BMD at the lumbar spine as assessed by dual energy X-ray absorptiometry (DEXA) in steroid-treated patients not receiving any supportive drugs was -0.3 to -3.23% over a 12-month period (28) (29) (30) (31) . Corticosteroids also increase bone resorption, which may be mediated by parathyroid hormone-mediated activation of osteoclasts. NTx is produced by osteoclasts in the bone as a degradation product of type I collagen. Since NTx reflects the activity of osteoclasts, it is often used as a marker of bone resorption.
A meta-analysis has suggested that vitamin D3 may prevent steroid-induced osteoporosis (31) . In patients with glomerular diseases, vitamin D3 has been reported to exert a protective effect against steroid-induced loss of BMD after 8 weeks of administration (32) . In a previous study, the BMD in steroid-treated patients receiving vitamin D3 alone was significantly decreased after 12 months of treatment as compared with that at the baseline (15, 32) . We felt that the decrease of the BMD in the patients treated with alfacalcidol alone in our study was rather marked. Nakayamada et al (32) reported that the change in the BMD at the lumbar spine in patients with autoimmune diseases treated with high-dose corticosteroids and 1 μg/day of alfacalcidol for 1 year was -10.3%. Summarizing these findings, vitamin D3 alone may not be sufficient to prevent the loss of BMD caused by high-dose or long-term corticosteroid therapy.
In patients with nephrotic syndrome, the serum 25-hydroxyvitamin D levels are reduced and an inverse correlation exists between the serum 25-hydroxyvitamin D levels and urinary protein excretion rate (27) . Since we did not assess the serum vitamin D levels in the present patients, the effect of proteinuria on the reduction of the BMD could not be completely excluded. However, there was no significant difference in the urinary protein excretion level between the groups. We think that the effect of proteinuria on the reduction of the BMD also might not have differed between the groups.
Bisphosphonates are widely used to treat or prevent osteoporosis, and favorable results have been obtained in several large-scale trials. Bisphosphonates are structural analogues of pyrophosphates, but with a carbon atom bridging two phosphate residues, forming a P-C-P moiety. The bisphosphonates exert complex actions, including inhibition of the mevalonate enzyme pathway in osteoclasts and binding with hydroxyapatite crystals in the bone. They exert direct effects by decreasing the recruitment and suppressing the functions of osteoclasts, and indirect effects by stimulating osteoblasts to produce an inhibitor of osteoclast formation. Through their inhibitory effect on osteoclast activity without impairing bone architecture and mechanical strength, bisphosphonates have a cumulative inhibitory effect on the bone resorption and turnover, thereby increasing the bone mass and bone density (34) . Although (28) (29) (30) 33) , bisphosphonates are widely used as the most effective drugs to prevent steroid-induced osteoporosis and bone fractures, based on the results of many clinical trials, few trials have been carried out until date to determine the preventive effect of bisphosphonate therapy on steroid-induced osteoporosis in patients with MCNS.
In the present study, we focused on patients with MCNS, which might itself affect the metabolism of bone (23) , and examined whether a bisphophonate might suppress the steroid-induced loss of BMD in these patients. Although the BMD in the alfacalcidol-alone group decreased significantly, no significant change of the BMD was observed in the patients administered combined risedronate + alfacalcidol therapy. This finding suggests that bisphosphonates may also be effective for the prevention of steroid-induced osteoporosis in patients with MCNS. In many countries, including Japan (35) , bisphosphonates are recommended as the agents of first choice for preventing steroid-induced osteoporosis, and vitamin D or K as the agents of second choice. Our findings were also consistent with this guideline.
The factors influencing the likelihood of deterioration of the BMD were identified as the administration of risedronate, the cumulative dose of PSL, occurrence of relapse, and the baseline BMD. A meta-analysis reported the existence of a strong correlation between the cumulative dose of corticosteroid and the loss of BMD (36) . Increase of the cumulative dose of prednisolone was dependent on the occurrence of relapse. In our previous study, the relapse group showed a significantly higher incidence of corticosteroid side effects, such as osteoporosis (37) . The BMD at the baseline was significantly high, and the urinary NTx and serum ALP levels at the baseline tended to be high as compared with that at the 12-month observation. This finding suggests that the patients with a higher baseline bone turnover, which may be related to genetic factors (38, 39) , may be at a higher risk of loss of BMD associated with corticosteroid therapy.
In conclusion, the loss of BMD associated with high-dose and/or long-term corticosteroid therapy could be prevented by administration of a bisphosphonate, such as risedronate. In patients with MCNS receiving steroids, administration of a bisphosphonate might be advisable. High levels of BMD at the baseline, the cumulative dose of PSL, administration of risedronate, and the occurrence of relapse may influence the likelihood of development of steroid-induced osteoporosis in patients with MCNS.
